Medroxyprogesterone (When ATH: G03DA02)
When ATH:
G03DA02
Characteristic.
White or off-white crystalline powder, stable in air. Soluble in acetone and dioxane, partially - in ethanol and methanol, hard - to ether, insoluble in water.
Pharmacological action.
Progestogens, contraceptive, antitumor.
Application.
Contraception, particularly in women of reproductive age late; inoperable, recurrent and metastatic carcinoma of the endometrium and kidney (More palliative care), hormone-dependent forms of recurrent breast cancer in postmenopausal women.
Inside - secondary amenorrhea, dysfunctional uterine bleeding, premenstrual syndrome, vasomotor symptoms of menopause, endometriosis, Diagnosis of primary and secondary amenorrhea, prevention and treatment of osteoporosis in post-menopausal (in combination with estrogen and calcium preparations), the prevention of endometrial changes during estrogen replacement therapy in postmenopausal women.
Contraindications.
Hypersensitivity, tromboflebit, syndrome or thromboembolic stroke anamnesis, liver disease, vaginal bleeding unknown etiology, pregnancy, lactation (stop).
Side effects.
Menstrual irregularities, thromboembolism, insomnia, irritability, drowsiness, feeling tired, weakness, depression, dizziness, headache, swelling, nausea, pain and discomfort in the abdomen, breast tenderness, galactorrhea, cervical erosion, girsutizm, alopecia, fever, weight change, moon face, osteoporosis, hives, itch, acne, anafilaktoidnыe reactions and anaphylaxis.
Cooperation.
Aminoglutethimide reduces plasma concentrations and reduces efficiency.
Dosing and Administration.
/ M, as a contraceptive and to relieve vasomotor symptoms in menopause - 150 mg 1 once every 3 Months; Endometriosis by 50 mg 1 weekly or 100 mg 1 once every 2 week course at least 6 Months.
B /, endometrial cancer or kidney disease - 400-1000 mg weekly, when the clinical improvement - 400 mg 1 once a month.
Inside, endometrial cancer or kidney disease - 200-600 mg / day, breast cancer - 400-1200 mg / day. For the prevention and treatment of osteoporosis in postmenopausal women - by 12-15 25 month 5-10 mg 1 once a day.
Precautions.
The first method should be used only 5 day of a normal menstrual period (guarantee the absence of pregnancy). It is necessary to use an additional method of contraception during 2 weeks after the first injection. Every three months, we recommend injections (increases the reliability of contraception). When the cycle changes while receiving needed medical consultation. In dysfunctional uterine bleeding necessarily exclude uterine cancer and other organic lesions. Suspected development thrombophilic states (tromboflebit, cerebrovascular disorders, thromboembolism pulmonary artery branches, pochechnыy thrombosis) calls for immediate abolition of. Care should be taken in epilepsy, migraine, asthma, cardiac and renal failure, Given the potential for fluid retention. Be wary appoint diabetes, depressive states.
Cautions.
While taking medroxyprogesterone may change the results of a series of laboratory tests (incl. sulfabromoftaleinovogo and other liver function tests) - Reducing the level of steroids in plasma and urine (progesterone, Estradiol, pregnanediol, Testosterone, Cortisol), honadotropynov, globulin, sex hormone binding, level T3, elevated levels of prothrombin, Factor VII, VIII, IX, X.
